Anemia specialist Akebia merges with Keryx on the eve of a blockbuster brawl with FibroGen
Akebia is going into its head-to-head late-stage fight with FibroGen with a little more firepower.
Two months after Keryx $KERX CEO Gregory Madison abruptly resigned and left the company, the biotech has followed through today by agreeing to a merger with Akebia $AKBA, a biotech with a closely-watched anemia drug in late-stage development.
The combination of the two companies will bring together two drugs designed for patients with chronic kidney disease. Keryx markets Auryxia, which accounted for the lion’s share of about $22 million in Q1 revenue. That drug is used to fight iron deficiency anemia in patients with chronic kidney disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.